Trial Profile
Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Angioid streaks; Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms EYLEA-STRIE
- 24 Aug 2015 New trial record